+1 877 302 8632
+1 888 205 9894 (Toll-free)

SARS-CoV-2 Envelope antibody (SARS-CoV-2 E) (N-Term) Primary Antibody

SARS-CoV-2 E Reactivity: SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2) ELISA, IF, IHC Host: Rabbit Polyclonal unconjugated
Pubmed (9)
Catalog No. ABIN1031551
Plus shipping costs $45.00
0.1 mg ABIN1031551
0.1 mg ABIN1031551
local_shipping Shipping to: United States
Delivery in 2 to 3 Business Days
  • Target
    SARS-CoV-2 Envelope (SARS-CoV-2 E)
    Binding Specificity
    • 2
    • 2
    • 1
    SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
    • 6
    This SARS-CoV-2 Envelope antibody is un-conjugated
    • 5
    • 1
    ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC)
    • 5
    • 4
    • 2
    • 1
    Predicted Reactivity
    Predicted reactivity based on immunogen sequence: SARS-CoV Envelope proteins: (100%)
    Affinity chromatography purified via peptide column
    Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody was raised against a peptide corresponding to 10 amino acids near the amino terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope protein.
    The immunogen is located within the first 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope.
  • Application Notes
    SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody can be used for the detection of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope protein in ELISA. It will detect 20 ng of free peptide at 1 μg/mL.
    For Research Use only
  • Format
    1 mg/mL
    The antibody is supplied in PBS containing 0.02% sodium azide.
    Sodium azide
    Precaution of Use
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Handling Advice
    As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
    4 °C/-20 °C
    Storage Comment
    The antibody can be stored at 4 ˚ C for three months and -20 ˚ C, stable for up to one year.
    Expiry Date
    12 months
  • Magro, Mulvey, Laurence, Sanders, Crowson, Grossman, Harp, Nuovo: "The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series." in: The British journal of dermatology, Vol. 184, Issue 1, pp. 141-150, 2021 (PubMed).

    Vojdani, Vojdani, Kharrazian: "Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases." in: Frontiers in immunology, Vol. 11, pp. 617089, 2021 (PubMed).

    Magro, Mulvey, Berlin, Nuovo, Salvatore, Harp, Baxter-Stoltzfus, Laurence: "Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases." in: Translational research : the journal of laboratory and clinical medicine, Vol. 220, pp. 1-13, 2020 (PubMed).

    Mulvey, Magro, Ma, Nuovo, Baergen: "Analysis of complement deposition and viral RNA in placentas of COVID-19 patients." in: Annals of diagnostic pathology, Vol. 46, pp. 151530, 2020 (PubMed).

    Nuovo, Tili, Suster, Matys, Hupp, Magro et al.: "Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG ..." in: Annals of diagnostic pathology, Vol. 48, pp. 151600, 2020 (PubMed).

    Yurkovetskiy, Wang, Pascal, Tomkins-Tinch, Nyalile, Wang, Baum, Diehl, Dauphin, Carbone, Veinotte, Egri, Schaffner, Lemieux, Munro, Rafique, Barve, Sabeti, Kyratsous, Dudkina, Shen, Luban: "Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant." in: Cell, Vol. 183, Issue 3, pp. 739-751.e8, 2020 (PubMed).

    Schöler, Le-Trilling, Eilbrecht, Mennerich, Anastasiou, Krawczyk, Herrmann, Dittmer, Trilling: "A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds." in: Frontiers in immunology, Vol. 11, pp. 573526, 2020 (PubMed).

    Nuovo, Magro, Mikhail: "Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx." in: Annals of diagnostic pathology, Vol. 48, pp. 151565, 2020 (PubMed).

    Ventura, Cennamo, Minopoli, Campanile, Censi, Terracciano, Portella, Velotta: "Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs." in: ACS sensors, Vol. 5, Issue 10, pp. 3043-3048, 2020 (PubMed).

  • Target
    SARS-CoV-2 Envelope (SARS-CoV-2 E)
    Alternative Name
    SARS-CoV-2 Envelope Protein
    envelope protein, E
    Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak. The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.
    Gene ID
    NCBI Accession
You are here:
help Support